Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies. In addition, the company is developing BLU-782, a discovery program targeting the kinase ALK2 for the treatment of fibrodysplasia ossificans progressiva, a rare genetic disease caused by mutations in the ALK2 gene, ACVR1. The company has an agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to discover, develop, and commercialize small molecule therapeutics targeting kinases. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-374-7580
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$21.43 million
Profitability
Miscellaneous
Employees149
OptionableOptionable
Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions
What is Blueprint Medicines' stock symbol?
Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."
How were Blueprint Medicines' earnings last quarter?
Blueprint Medicines Corp (NASDAQ:BPMC) announced its quarterly earnings results on Tuesday, October, 30th. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts' consensus estimates of ($1.57) by $0.09. The biotechnology company had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.87 million. Blueprint Medicines had a negative net margin of 455.15% and a negative return on equity of 36.72%. Blueprint Medicines's revenue was down 86.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.96) earnings per share. View Blueprint Medicines' Earnings History.
When is Blueprint Medicines' next earnings date?
What price target have analysts set for BPMC?
5 analysts have issued 12 month price objectives for Blueprint Medicines' shares. Their predictions range from $102.00 to $105.00. On average, they expect Blueprint Medicines' stock price to reach $103.25 in the next twelve months. This suggests a possible upside of 33.7% from the stock's current price. View Analyst Price Targets for Blueprint Medicines.
What is the consensus analysts' recommendation for Blueprint Medicines?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Blueprint Medicines.
Has Blueprint Medicines been receiving favorable news coverage?
Headlines about BPMC stock have trended neutral recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Blueprint Medicines earned a daily sentiment score of 0.3 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near term.
Who are some of Blueprint Medicines' key competitors?
Some companies that are related to Blueprint Medicines include Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT), Dr.Reddy's Laboratories (RDY) and Amarin (AMRN).
Who are Blueprint Medicines' key executives?
Blueprint Medicines' management team includes the folowing people:
- Mr. Jeffrey W. Albers, CEO, Pres & Director (Age 47)
- Mr. Alexis A. Borisy, Co-Founder & Director (Age 46)
- Mr. Michael Landsittel, VP of Fin. (Age 46)
- Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 55)
- Ms. Kathryn Haviland, Chief Bus. Officer (Age 42)
When did Blueprint Medicines IPO?
(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Blueprint Medicines' major shareholders?
Blueprint Medicines' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.85%), Partner Fund Management L.P. (3.35%), Hillhouse Capital Advisors Ltd. (3.26%), Perceptive Advisors LLC (1.95%), Eagle Asset Management Inc. (1.73%) and Casdin Capital LLC (1.46%). Company insiders that own Blueprint Medicines stock include Anthony L Boral, Daniel Lynch, George Demetri, Jeffrey W Albers, Kate Haviland, Marion Dorsch, Mark J Levin and Nicholas Lydon. View Institutional Ownership Trends for Blueprint Medicines.
Which major investors are selling Blueprint Medicines stock?
BPMC stock was sold by a variety of institutional investors in the last quarter, including Casdin Capital LLC, Perceptive Advisors LLC, Citigroup Inc., Millennium Management LLC, Jennison Associates LLC, Barclays PLC, Tekla Capital Management LLC and Eagle Asset Management Inc.. Company insiders that have sold Blueprint Medicines company stock in the last year include George Demetri, Jeffrey W Albers, Marion Dorsch and Nicholas Lydon. View Insider Buying and Selling for Blueprint Medicines.
Which major investors are buying Blueprint Medicines stock?
BPMC stock was purchased by a variety of institutional investors in the last quarter, including Hillhouse Capital Advisors Ltd., Foresite Capital Management III LLC, Lord Abbett & CO. LLC, Artal Group S.A., Two Sigma Investments LP, Westfield Capital Management Co. LP, Geode Capital Management LLC and Partner Fund Management L.P.. View Insider Buying and Selling for Blueprint Medicines.
How do I buy shares of Blueprint Medicines?
Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Blueprint Medicines' stock price today?
One share of BPMC stock can currently be purchased for approximately $77.20.
How big of a company is Blueprint Medicines?
Blueprint Medicines has a market capitalization of $3.39 billion and generates $21.43 million in revenue each year. The biotechnology company earns $-148,110,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Blueprint Medicines employs 149 workers across the globe.
What is Blueprint Medicines' official website?
How can I contact Blueprint Medicines?
Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]
MarketBeat Community Rating for Blueprint Medicines (NASDAQ BPMC)
MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote "Outperform" if you believe BPMC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPMC will underperform the S&P 500 over the long term. You may vote once every thirty days.
